The microbiome and immune system interact, shape one another, and can be engineered to improve outcomes.
For generations, tumors were imagined as sterile fortresses — islands of disease sealed off from the microbial world that inhabits the rest of us. Researchers at UC Davis have now found that soft tissue sarcomas harbor their own microbial communities, and that these communities speak to the immune system in ways that may determine whether a cancer spreads or is held at bay. The discovery, drawn from a small but carefully observed cohort of sarcoma patients, suggests that the boundary between the body's inner ecology and its diseases is far more porous — and far more consequential — than medicine had assumed.
- Sarcoma tumors, long believed to be microbe-free, have been found to contain measurable microbial populations — overturning a foundational assumption in cancer biology.
- The composition of a tumor's microbiome at the moment of diagnosis may already be signaling something about how the patient will fare, creating urgency around understanding what those microbial signals mean.
- Viruses within the tumor — including Respirovirus, ordinarily associated with respiratory illness — appear to actively recruit natural killer cells, the immune system's most aggressive cancer fighters.
- Higher concentrations of natural killer cells inside tumors correlate with lower rates of metastasis and better survival, giving researchers a concrete biological lever to pursue.
- UC Davis scientists are now investigating whether engineered viruses could be deployed to amplify this immune recruitment, turning a naturally occurring phenomenon into a deliberate therapeutic strategy.
Soft tissue sarcomas — cancers arising in muscle, fat, and nerve tissue — were long assumed to be sterile environments, untouched by the microbial communities that colonize the rest of the human body. A team at UC Davis Comprehensive Cancer Center has now challenged that assumption in a study published in the Journal for Immunotherapy of Cancer, finding that these tumors do harbor measurable microbial populations, and that those populations may influence how effectively the immune system mounts a defense.
The research followed 15 adult patients with non-metastatic soft tissue sarcoma, most at advanced stage III, over a median period of 24 months. Tumor tissue was analyzed through genetic sequencing and immune profiling, while stool samples were collected for comparison. What emerged was a striking correlation: the quantity of microbiome present in a tumor at diagnosis appeared linked to patient prognosis — a finding made more significant by the fact that sarcomas were previously thought to contain no microbes at all.
The mechanism centers on immune recruitment. Viruses within the tumor microbiome — particularly Respirovirus — were found to attract natural killer cells, among the body's most potent defenses against cancer. The greater the infiltration of these cells into tumor tissue, the lower the risk of metastasis and the better the patient's survival odds. Lead author Robert Canter, chief of Surgical Oncology at UC Davis, described the microbiome and immune system as deeply entangled systems that shape one another in ways medicine is only beginning to map.
Building on this, the team is now exploring whether engineered viruses could be designed to deliberately draw more natural killer cells into tumors — essentially amplifying a process that nature has already demonstrated is possible. The implications extend well beyond sarcoma: microbiomes have been documented inside breast, lung, pancreatic, and melanoma tumors as well, suggesting that the relationship between tumor ecology and immune response may be a universal feature of cancer biology worth investigating across the full spectrum of the disease.
Soft tissue sarcomas—cancers that grow in muscle, fat, and nerve tissue—were long thought to be sterile environments, free of the microbial communities that populate the rest of the human body. Researchers at UC Davis Comprehensive Cancer Center have now upended that assumption. In a study published in the Journal for Immunotherapy of Cancer, they found that these tumors do in fact harbor measurable populations of microorganisms, and that the presence and composition of these microbial communities may shape how well a patient's immune system can fight back.
The discovery emerged from work with 15 adult patients who had non-metastatic soft tissue sarcoma. Most of their tumors were advanced stage III, and two-thirds affected the limb. The team collected tumor tissue and stool samples, then sent the tumor samples to UC Davis's Genome Center for genetic sequencing and to the Flow Cytometry Shared Resource Laboratory for immune profiling. Over a median follow-up period of 24 months, researchers tracked how these patients responded to treatment.
What they found was striking: the amount of microbiome present in a tumor at the time of diagnosis appeared to correlate with the patient's prognosis. Though the microbial populations within tumors are small compared to those in the gut or other body sites, the finding matters precisely because sarcomas were believed to be free of microbes altogether. Robert Canter, the study's lead author and chief of the Division of Surgical Oncology, emphasized that this opens a new avenue for understanding how cancer develops and spreads. The microbiome and immune system, he noted, do not exist in isolation—they interact, shape one another, and can potentially be engineered to improve outcomes.
The mechanism appears to work through immune recruitment. Viruses within the tumor microbiome seem to attract specific types of immune cells, particularly natural killer cells, which are among the body's most potent cancer fighters. The study found a strong positive correlation between the presence of Respirovirus—a genus of viruses typically associated with respiratory illness—and the abundance of natural killer cells in sarcoma tissue. This matters because the more natural killer cells that infiltrate a tumor, the lower the risk that the cancer will metastasize to distant sites. Higher natural killer cell presence also correlates with better survival rates.
Canter and his colleagues are now exploring whether they could engineer viruses to deliberately attract more of these cancer-killing immune cells to tumors. The logic is straightforward: if naturally occurring viruses in the microbiome can recruit immune fighters, perhaps designed viruses could do so more effectively, amplifying the body's own defenses against the disease.
The finding is not isolated to sarcoma. Past research has documented the presence of microbiomes within tumors across multiple cancer types—breast, lung, pancreas, and melanoma among them. Canter said this suggests that the relationship between tumor microbiome and immune response warrants investigation across the full spectrum of cancer types. As the field has come to understand that the gut microbiome shapes immune function throughout the body and influences how patients respond to immunotherapy, the discovery that tumors themselves harbor microbial communities adds another layer to that picture. The microbiome, it turns out, is not just something that lives in us—it lives in our cancers too, and understanding how to harness that fact could reshape how we treat the disease.
Citações Notáveis
The microbiome in the gut and other parts of the body has a major impact on human health and disease, shapes the immune system throughout the body, and has a big role in how the body responds to cancer and cancer treatments like immunotherapy.— Robert Canter, lead author and chief of the Division of Surgical Oncology
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that sarcomas have a microbiome if the bacterial load is so small?
Because we thought they were sterile. That assumption shaped how we thought about the tumor environment. Once you realize microbes are there, you can ask what they're doing—and it turns out they're recruiting immune cells that kill cancer.
So the viruses are helping the patient's immune system?
In some cases, yes. The presence of certain viruses correlates with more natural killer cells in the tumor, which means better survival odds. But we don't fully understand the mechanism yet. That's what makes this worth pursuing.
Could you engineer a virus to do this deliberately?
That's the next question. If naturally occurring viruses attract immune fighters, why not design ones that do it more reliably? It's speculative, but it's the kind of thinking that could change how we use immunotherapy.
What about the patients in this study—did they do better than expected?
The study tracked them for two years as part of their regular cancer care. Most had advanced tumors affecting their limbs. The microbiome findings don't tell us they survived longer, but they tell us which patients might have better odds based on what's in their tumor.
Is this specific to sarcoma?
No. Other cancers—breast, lung, pancreas, melanoma—also have microbiomes. This study is sarcoma-focused, but the principle likely applies more broadly. That's why the researchers think this deserves investigation across cancer types.